Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 1,100 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,100 shares of Pro-Dex stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $45.01, for a total value of $49,511.00. Following the completion of the sale, the director now owns 318,652 shares of the company’s stock, valued at approximately $14,342,526.52. The trade was a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Pro-Dex Trading Down 7.0 %

Shares of Pro-Dex stock opened at $35.30 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 2.58. Pro-Dex, Inc. has a 52 week low of $16.18 and a 52 week high of $59.60. The stock has a 50 day moving average price of $47.43 and a two-hundred day moving average price of $34.74. The stock has a market capitalization of $115.08 million, a PE ratio of 17.56 and a beta of 0.53.

Pro-Dex (NASDAQ:PDEX) last announced its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. As a group, equities analysts anticipate that Pro-Dex, Inc. will post 2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PDEX. StockNews.com lowered shares of Pro-Dex from a “strong-buy” rating to a “buy” rating in a research note on Monday. Ascendiant Capital Markets upped their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a report on Monday, November 11th.

Institutional Investors Weigh In On Pro-Dex

Institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC increased its holdings in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Pro-Dex by 7.9% during the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after buying an additional 900 shares during the last quarter. Bard Associates Inc. grew its holdings in Pro-Dex by 17.6% during the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after buying an additional 2,031 shares in the last quarter. Ritholtz Wealth Management purchased a new stake in Pro-Dex in the 4th quarter valued at $572,000. Finally, JPMorgan Chase & Co. lifted its stake in Pro-Dex by 2.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after acquiring an additional 529 shares in the last quarter. Institutional investors and hedge funds own 15.28% of the company’s stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.